Abstract: Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

Abstract: A method for providing contents in a mobile communication system, the method comprising searching subscriber information of client information of the mobile terminal connected with a wireless internet, performing an authentication of the subscriber information, transmitting an inquiry message as to whether to be affiliated with a wireless internet to the mobile terminal in the case that a subscriber has a due right but didn't register to a wireless internet in the authenticating result, and automatically affiliating with a wireless internet in the case that a terminal of the subscriber receives an agreement message of an affiliation with a wireless internet. The automatically affiliating with a wireless internet comprising generating a predetermined provisional data for affiliating except for the subscriber information and apparatus information of the subscriber terminal of data requested in case of being affiliated with the wireless internet.

Abstract: A method for estimating an SOC-OCV profile by degradation of a secondary battery according to an embodiment of the present disclosure includes individually obtaining an SOC-OCV profile (a first profile) of a cathode of the secondary battery and an SOC-OCV profile (a second profile) of an anode of the secondary battery using a half cell; obtaining a new SOC-OCV profile (a third profile) of the cathode by reflecting a level of degradation (a %) by use of the secondary battery to modify the SOC-OCV profile of the cathode, but setting only an SOC range to be narrow in proportion to the level of degradation while maintaining an OCV range of the cathode as it is; obtaining a new SOC-OCV profile (a fourth profile) of the anode by migrating the SOC-OCV profile of the anode in a horizontal direction taking into account the level of degradation by use of the secondary battery; and obtaining a new SOC-OCV profile (a fifth profile) by determining a subtraction of an OCV value by the SOC-OCV profile of the anode from an O

Abstract: The present invention provides a method for producing dried bio-cellulose which, according to one embodiment of the present invention, prevents contamination caused by microorganisms during the transport and production processes, does not require an additional anti-microorganism system in the production process, and can reduce the cost of transport and production by being stored at room temperature for a long time. Also, according to one embodiment of the present invention, the dried bio cellulose can be used as a cosmetic or pharmaceutical material for delivering medicinal substances through prompt gelation in several seconds or minutes.

Abstract: The present invention provides a method for producing dried bio-cellulose which, according to one embodiment of the present invention, prevents contamination caused by microorganisms during the transport and production processes, does not require an additional anti-microorganism system in the production process, and can reduce the cost of transport and production by being stored at room temperature for a long time. Also, according to one embodiment of the present invention, the dried bio cellulose can be used as a cosmetic or pharmaceutical material for delivering medicinal substances through prompt gelation in several seconds or minutes.

Abstract: Disclosed is a quenching circuit including an avalanche photodiode and a quenching diode applying a bias voltage to the avalanche photodiode. Since the quenching circuit includes the quenching diode instead of a quenching resistor, the avalanche photodiode can quickly recover to linear mode from Geiger mode, and the bias voltage applied to the avalanche photodiode is stably maintained even though a current level of the avalanche photodiode fluctuates according to the intensity of incident light.

Abstract: Disclosed are a compound related to inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (especially humans). The compound has a structural formula I.

Abstract: The present disclosure discloses a system and method of adjusting an output parameter of a secondary battery. The system according to the present disclosure determines a voltage, a current, and a temperature of the secondary battery, determines a state of charge of the secondary battery using the current, determines a deration target current value calculated from a maximum value of a predefined resistance change rate, which corresponds to the state of charge and the temperature, and an output maintaining time, when the voltage of the secondary battery decreases to a preset threshold voltage or lower, and provides an output parameter including at least one of the deration target current value and a deration target output value determined therefrom to a control system of a load device supplied with power from the secondary battery.

Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).

Abstract: Disclosed is an apparatus and method for estimating a parameter of a secondary battery. The apparatus according to the present disclosure includes a sensor means configured to measure a plurality of current-voltage data while a charging current decreases when a secondary battery is charged in such a pattern that the charging current increases to a peak value and then decreases, and a control means configured to receive an input of the plurality of current-voltage data from the sensor means, calculate a linear approximation equation representing a correlation between a current and a voltage from the plurality of current-voltage data, and estimate a Y intercept of the linear approximation equation as an open-circuit voltage of the secondary battery.

Abstract: A wheel bearing includes a hub provided with a flange; and an outer ring having an end close to the flange and the other end opposite to the end and relatively rotatable to the hub. A sealing structure for sealing the space between the flange and the end of the outer ring is further included.

Abstract: Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

Abstract: Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a ROR? mediated disease. The compound has the structural formula (I).

Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).

Abstract: Provided is a random access method of a node, the method including receiving spatial group information on spatial groups generated in a cell from a base station, identifying a spatial group corresponding to the node based on the spatial group information, transmitting a preamble signal to the base station by generating the preamble signal, and receiving a random access response message in response to the preamble signal.

Abstract: The present invention relates to a photosensitive resin composition and a photosensitive material comprising the same. The photosensitive resin composition according to an exemplary embodiment of the present invention may comprise two multi-functional monomers where structures of side chains comprising unsaturated double bonds are different from each other while a composition ratio is changed. Accordingly, in the exemplary embodiment of the present invention, processability is excellent, and it is possible to decrease defects by a rupture when a LCD substrate is sealed and substrate separation defects due to an impact to the LCD products by improving an adhesion property to a lower substrate after a hard baking process.

Abstract: A silicone-containing compound is an additive for a lithium secondary battery electrolyte for improving high-temperature lifetime characteristics and/or high-temperature stability of a lithium secondary battery. An electrolyte for a lithium secondary battery includes the silicon-containing compound. A lithium secondary battery includes the electrolyte. A method of preparing the silicon-containing compound is also provided.

Abstract: A polymer electrolyte for a lithium secondary battery includes a polymer represented by Formula 1 below, wherein a and b are each independently an integer from 1 to 5, and n is an integer from 1 to 1,000. A lithium secondary battery includes the polymer electrolyte.

Abstract: Disclosed is an apparatus and method for estimating a SOC of a secondary battery containing a blended cathode material. The SOC estimating apparatus estimates a SOC of a secondary battery including a cathode having a blended cathode material containing a first cathode material and a second cathode material with different operating voltage ranges, an anode having an anode material, and a separator for separating the cathode from the anode, and the apparatus includes a sensor configured to measure a discharge inception voltage and a final discharge voltage when the secondary battery is discharged for a predetermined time, and a control unit configured to estimate SOC of the secondary battery corresponding to the measured discharge inception voltage and the measured final discharge voltage by using a predetermined relationship between the discharge inception voltage and the final discharge voltage and the SOC of the secondary battery.

Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.